ClinicalTrials.gov posted results on 2 September 2026 for a Phase 2 study of pembrolizumab followed by involved site radiotherapy in early-stage relapsed or primary refractory classical Hodgkin lymphoma. The trial enrolled 22 participants; posted measurements reported complete and overall response counts across CMR, PMR/SD, and POD groups.
Background
The study evaluated pembrolizumab with involved site radiotherapy in patients with relapsed or refractory early-stage classical Hodgkin lymphoma. Its stated purpose was to assess the safety and effectiveness of this treatment strategy and determine whether it could cure a significant number of patients while avoiding the toxicity of either treatment alone. The registry listed pembrolizumab as the intervention.
Trial design
This was a Phase 2 study identified as NCT03179917. It enrolled 22 participants with Hodgkin lymphoma and was listed as active, not recruiting, when the results were posted.
The study examined single-agent pembrolizumab followed by involved site radiotherapy. The posted outcome measurements were titled “Complete Response Rate Following Pembrolizumab-ISRT” and “Overall Response Rate Following Single-agent Pembrolizumab.” No primary outcome entries or statistical analyses were supplied in the record.
Key results
For the complete response outcome following pembrolizumab and involved site radiotherapy, one set of posted counts included 7 participants in the CMR group, 9 participants in the PMR/SD group, and 0 participants in the POD group. A second set included 0 participants in CMR, 1 participant in PMR/SD, and 5 participants in POD.
For overall response following single-agent pembrolizumab, one set included 7 participants in CMR, 8 participants in PMR/SD, and 0 participants in POD. A second set included 0 participants in CMR, 2 participants in PMR/SD, and 5 participants in POD.
The supplied data did not provide denominators for these groups, adverse-event findings, p-values, confidence intervals, or comparative analyses.
What this means
The registry record documents posted response-related participant counts from a Phase 2 study of pembrolizumab and involved site radiotherapy in relapsed or refractory early-stage Hodgkin lymphoma. Because group definitions, denominators, and statistical analyses were not supplied, the figures cannot establish response rates, treatment superiority, or the regimen’s safety profile.
Source
Source: ClinicalTrials.gov, registry record for “Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma,” NCT03179917, with results posted on 2 September 2026. The record is available at clinicaltrials.gov/study/NCT03179917.